The 10-second takeaway
For the quarter ended Aug. 31 (Q1), AngioDynamics missed slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share dropped to a loss.
Gross margins contracted, operating margins expanded, net margins contracted.
AngioDynamics reported revenue of $83.4 million. The six analysts polled by S&P Capital IQ expected to see revenue of $85.0 million on the same basis. GAAP reported sales were 53% higher than the prior-year quarter's $54.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.10. The six earnings estimates compiled by S&P Capital IQ forecast $0.09 per share. GAAP EPS were -$0.02 for Q1 versus $0.05 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 51.4%, 770 basis points worse than the prior-year quarter. Operating margin was 8.0%, 140 basis points better than the prior-year quarter. Net margin was -0.9%, 340 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $87.1 million. On the bottom line, the average EPS estimate is $0.10.
Next year's average estimate for revenue is $358.8 million. The average EPS estimate is $0.40.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 93 members out of 108 rating the stock outperform, and 15 members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 31 give AngioDynamics a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AngioDynamics is hold, with an average price target of $14.38.
- Add AngioDynamics to My Watchlist.